Neurosurgery was Integra Lifesciences Holdings’s largest segment in fiscal 2025, bringing in $827.67M of $1.64B (51%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurosurgery | $794.02M | $818.10M | $803.82M | $827.67M | |||||||||
| Wound Reconstruction & Care | $406.69M | $373.99M | $350.57M | $323.49M | |||||||||
| Wound Reconstruction | — | — | — | — | |||||||||
| Orthopedics | — | — | — | — | |||||||||
| Instruments | $192.68M | $203.62M | $204.18M | $206.47M | |||||||||
| Precision Tools & Instruments | — | — | — | — | |||||||||
| International | — | — | — | — | |||||||||
| U.S. Spine & Other | — | — | — | — | |||||||||
| U.S. Neurosurgery | — | — | — | — | |||||||||
| U.S. Instruments | — | — | — | — | |||||||||
| Private Label | $131.41M | $108.59M | $116.33M | $111.25M | |||||||||
| U.S. Extremities | — | — | — | — | |||||||||
| Ent | $32.87M | $37.28M | $135.64M | $166.37M | |||||||||
| Extremity Orthopedics | — | — | — | — | |||||||||
| Total | $1.56B | $1.54B | $1.61B | $1.64B |
Integra Lifesciences Holdings brought in $1.64B from its five segments in fiscal 2025, the year ended December 31, 2025. That was up 1.5% from $1.61B in fiscal 2024. Neurosurgery was the largest at $827.67M (50.6%), ahead of Wound Reconstruction & Care at $323.49M (19.8%) and Instruments at $206.47M (12.6%). The other two segments brought in $277.62M combined.
Compared with fiscal 2024, Ent grew fastest, up 22.7% to $166.37M, while Wound Reconstruction & Care fell the most, down 7.7% to $323.49M. From fiscal 2022 to 2025, combined revenue from these segments grew from $1.56B to $1.64B, a compound annual growth rate of 1.6%. Neurosurgery's share held steady at about 50.6%.
United States was Integra Lifesciences Holdings’s largest region in fiscal 2025, bringing in $1.20B of $1.64B (74%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.13B | $1.10B | $1.19B | $1.20B | ||||||||||
| United States (Includes Long-Lived Assets In Puerto Rico) | — | — | — | — | ||||||||||
| Europe | $170.90M | $165.22M | $158.50M | $162.67M | ||||||||||
| Asia Pacific | $176.48M | $193.10M | $176.61M | $189.25M | ||||||||||
| Rest Of World | — | — | — | — | ||||||||||
| Rest Of The World | $83.48M | $82.53M | $82.74M | $78.58M | ||||||||||
| Total | $1.56B | $1.54B | $1.61B | $1.64B |
Integra Lifesciences Holdings brought in $1.64B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 1.5% from $1.61B in fiscal 2024. United States was the largest at $1.20B (73.7%), ahead of Asia Pacific at $189.25M (11.6%) and Europe at $162.67M (9.9%). The remaining region, Rest Of The World, brought in $78.58M.
Compared with fiscal 2024, Asia Pacific grew fastest, up 7.2% to $189.25M, while Rest Of The World fell the most, down 5.0% to $78.58M. From fiscal 2022 to 2025, combined revenue from these regions grew from $1.56B to $1.64B, a compound annual growth rate of 1.6%. United States' share of the total rose from 72.3% to 73.7%.
Codman Specialty Surgical was Integra Lifesciences Holdings’s largest segment in fiscal 2025, bringing in $827.67M of $1.15B (72%).
| Statement Business Segments | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Codman Specialty Surgical | $794.02M | $818.10M | $803.82M | $827.67M | |||||||
| Specialty Surgical Solutions | — | — | — | — | |||||||
| Tissue Technologies | $406.69M | $373.99M | $350.57M | $323.49M | |||||||
| Orthopedics & Tissue Technologies | — | — | — | — | |||||||
| Total | $1.20B | $1.19B | $1.15B | $1.15B |
Integra Lifesciences Holdings brought in $1.15B from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $1.64B it reports by segment, so these segments do not cover all of its revenue. Codman Specialty Surgical was the largest at $827.67M (71.9%), ahead of Tissue Technologies at $323.49M (28.1%).
Compared with fiscal 2024, Codman Specialty Surgical grew 3.0% to $827.67M, while Tissue Technologies fell 7.7% to $323.49M.
Integra Lifesciences Holdings (IART) reports its revenue by segment, by geography and by statement business segments. In fiscal 2025, Neurosurgery was its largest segment, bringing in $827.67M (50.6% of the total), followed by Wound Reconstruction & Care at $323.49M (19.8%).
Neurosurgery was Integra Lifesciences Holdings' largest segment in fiscal 2025, bringing in $827.67M, or 50.6% of the $1.64B total across its five segments.
United States was Integra Lifesciences Holdings' largest region in fiscal 2025, bringing in $1.20B, or 73.7% of the $1.64B total across its four regions.
Among Integra Lifesciences Holdings' segments that make up at least 2% of revenue, Ent grew fastest in fiscal 2025, up 22.7% from $135.64M to $166.37M.
Every figure comes from Integra Lifesciences Holdings' annual financial filings, as reported. Each line keeps the name Integra Lifesciences Holdings gives it, and years follow its fiscal calendar.
Integra Lifesciences Holdings' revenue by segment goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.